Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Impact of Biplane Vena Contracta Width in Patients with Atrial Functional Mitral Regurgitation.

European heart journal. Cardiovascular Imaging·2026
Same author

Understanding Outcomes in Hemodialysis Patients Who Underwent Transcatheter Aortic Valve Replacement With the Latest Devices.

JACC. Asia·2026
Same author

Health Status Changes and Long-Term Clinical Outcomes in Patients With Atrial Fibrillation.

JAMA network open·2026
Same author

Sex differences in circulating microRNA profiles in heart failure with preserved and reduced ejection fraction.

European heart journal open·2026
Same author

Serial Assessment of Patient-Reported Health Status and Subsequent Clinical Outcomes in Atrial Fibrillation.

Circulation journal : official journal of the Japanese Circulation Society·2026
Same author

7-Year Outcomes of Balloon-Expandable Versus Self-Expanding Valves in Women Undergoing Transcatheter Aortic Valve Replacement.

JACC. Asia·2026

Related Experiment Video

Updated: Aug 6, 2025

Assessing Cardiomyocyte Subtypes Following Transcription Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts
09:29

Assessing Cardiomyocyte Subtypes Following Transcription Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts

Published on: March 22, 2017

7.5K

Development of direct cardiac reprogramming for clinical applications.

Yu Yamada1, Taketaro Sadahiro1, Masaki Ieda1

  • 1Department of Cardiology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba City, Ibaraki 305-8575, Japan.

Journal of Molecular and Cellular Cardiology
|March 14, 2023
PubMed
Summary

Direct cardiac reprogramming converts cardiac fibroblasts into cardiomyocyte-like cells to treat heart disease. This innovative therapy regenerates heart tissue and reverses fibrosis, offering a promising alternative to transplantation.

Keywords:
Cardiac fibroblastDirect cardiac reprogrammingHeart failureHeart regenerationMyocardial infarction

More Related Videos

Assessing Cardiac Reprogramming using High Content Imaging Analysis
06:02

Assessing Cardiac Reprogramming using High Content Imaging Analysis

Published on: October 26, 2020

1.3K
In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
05:04

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter

Published on: February 22, 2022

3.5K

Related Experiment Videos

Last Updated: Aug 6, 2025

Assessing Cardiomyocyte Subtypes Following Transcription Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts
09:29

Assessing Cardiomyocyte Subtypes Following Transcription Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts

Published on: March 22, 2017

7.5K
Assessing Cardiac Reprogramming using High Content Imaging Analysis
06:02

Assessing Cardiac Reprogramming using High Content Imaging Analysis

Published on: October 26, 2020

1.3K
In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
05:04

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter

Published on: February 22, 2022

3.5K

Area of Science:

  • Cardiovascular Research
  • Regenerative Medicine
  • Cardiac Biology

Background:

  • Cardiovascular diseases are a growing global health concern.
  • Cardiac regenerative therapy offers potential for treating ischemic heart disease.
  • Direct cardiac reprogramming is an emerging strategy for myocardial regeneration.

Purpose of the Study:

  • To review recent advancements in in vivo direct cardiac reprogramming.
  • To discuss the clinical prospects and challenges of cardiac reprogramming.
  • To highlight the potential of converting fibroblasts into cardiomyocyte-like cells.

Main Methods:

  • Utilizing defined factors to induce transdifferentiation of cardiac fibroblasts (CFs) into induced cardiomyocyte-like cells (iCMs) in vivo.
  • Demonstrating the efficacy of in vivo reprogramming in improving cardiac function and reducing scar area post-myocardial infarction (MI).
  • Investigating the dual role of reprogramming in myocardial regeneration and fibrosis reversal through fibroblast quiescence.

Main Results:

  • In vivo cardiac reprogramming improves cardiac contractile function after acute MI.
  • Reprogramming reduces scar size in infarcted hearts.
  • Recent findings show reprogramming reverses fibrosis and improves heart failure in chronic MI by quieting pro-fibrotic fibroblasts.

Conclusions:

  • In vivo cardiac reprogramming is a promising regenerative therapy for heart failure.
  • The approach regenerates myocardium and combats fibrosis.
  • Future clinical applications are promising, but direct human reprogramming faces challenges.